Why the study?
Does switching to aripiprazole improve non-HDL cholesterol in patients with schizophrenia or schizoaffective disorder with metabolic risk factors?
Population
215 patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density…
Comparison
Switch to aripiprazole for 24 weeks, with all… vs Stay on current medication for 24 weeks, with…
Design
RCT, randomly assigned, Clinical raters were blinded to treatment assignment
Follow-up
24 weeks
Authors
Loading...
Supports switching to aripiprazole for lipid benefits in schizophrenia; extends RCT metabolic data while flagging higher discontinuation.
Does switching to aripiprazole improve non-HDL cholesterol in patients with schizophrenia or schizoaffective disorder with metabolic risk factors?
Switching from high metabolic risk antipsychotics to aripiprazole improves non-HDL cholesterol and weight, though it is associated with higher treatment discontinuation.
Stroup et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: